Use of cytoprotective agents in the treatment of gastric ulcers.
D000535:Aluminum / Q000494:pharmacology / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001729:Bismuth / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002229:Carbenoxolone / Q000378:metabolism / Q000627:therapeutic use; D004341:Drug Evaluation; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism; D005756:Gastritis / Q000150:complications / Q000503:physiopathology; D006801:Humans; D009942:Organometallic Compounds; D011453:Prostaglandins / Q000378:metabolism / Q000627:therapeutic use; D013276:Stomach Ulcer / Q000209:etiology / Q000517:prevention & control*; D013392:Sucralfate
D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D011453:Prostaglandins; D013392:Sucralfate; D000535:Aluminum; C002791:bismuth tripotassium dicitrate; D002229:Carbenoxolone; D001729:Bismuth